To cite this paper use one of the standards below:
Despite of recent new advances in the cancer therapy knowledge, it remains one of the most malignant diseases worldwide, according to The World Health Organization (W.H.O, 2018). In the last 50 years, the secondary metabolites from microorganisms have gained importance as they inspire researchers from different areas on new drug development for cancer treatment. The main sources of new natural anticancer agents have been plants and microorganisms which provided around 49% of the new anticancer drugs, from 1940 and 2014, either as natural products or natural product derivatives (DEMAIN; VAISHNAV, 2011; NEWMAN; CRAGG, 2016). In this work, we search for new antitumoral agents from environmental bacteria isolated from soil. Bacteria were previously isolated from environmental sources and deposited at the Rhizobacteria collection of the Universidade Federal de Santa Catarina – Campus de Curitibanos - SC. Isolates for seven bacteria (RLB06 (actinomiceto), RLB02 (actinomiceto), EB27 (Bacillus sp), BDG (bacteria Isolate), BTE (bacteria Isolate), CBS05 (pseudomonas sp.) CBSAL05 (Pseudomonas spp.) were grown in 500 mL of Luria Bertani solid medium (LB) at 30ºC, for 7 days. Then, the culture broth was centrifuged for separation of bacterial cells and supernatant was extracted with ethyl acetate (5 x 100 mL). The organic layers were combined, dried using anhydrous sodium sulfate and the solvent was evaporated yielding 10.2 mg for RLB06, 22.4 mg for RLB02, 57.5 mg for EB27, 42.3 mg for BDG, 67.6 mg for BTE, 56.4 mg for CBS05 and 18.5 mg for CBSAL05). The centrifuged bacterial cells were stored for future extract preparation. The antitumoral activity of the extracts were tested on a human pancreatic cancer cell line (PANC-1). Crescent concentrations were assayed (1-100 µg mL-1) in 72 hours of incubation. In addition, plant extract presenting antitumoral effect were tested on a human non-tumoral cell line (HUVEC) in order to calculate the selectivity index (SI), calculated by dividing the CC50 (cytotoxic concentration to 50% of cells) found for the non-tumoral by tumoral cell line. Cell viability was evaluated by resazurin reagent reduction assay and CC50 values were calculated based on the sigmoid concentration-response curve. Among tested bacteria extracts, only CBS05 reduced cell viability for PANC-1 presenting a CC50 of 37.8 ± 5.6 mg mL-1. When CBS05 crude extract was evaluated in HUVEC, a CC50 value of 52.4 ± 4.3 mg mL-1 was determined indicating a SI of 1.4 which is much better than gemcitabine, gold standard drug to pancreatic cancer, that induced a SI lower than 1.0 indicating low specificity for cancer cells. The results indicate the potential of edaphic bacteria in the development of new antitumoral agents. Other bacterial isolates will be evaluated, and the most active extracts will be produced in large scale for in vivo antitumoral assays and isolation of the active substances.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper